Cargando…

Multimodality Management of “Borderline Resectable” Pancreatic Neuroendocrine Tumors: Report of a Single-Institution Experience

BACKGROUND: Pancreatic neuroendocrine tumors (PanNETs) constitute approximately 3% of pancreatic neoplasms. Like patients with pancreatic ductal adenocarcinoma (PDAC), some of these patients present with “borderline resectable disease.” For these patients, an optimal treatment approach is lacking. W...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ambe, Chenwi M., Nguyen, Phuong, Centeno, Barbara A., Choi, Junsung, Strosberg, Jonathan, Kvols, Larry, Hodul, Pamela, Hoffe, Sarah, Malafa, Mokenge P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2017
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5937248/ https://www.ncbi.nlm.nih.gov/pubmed/28975822 http://dx.doi.org/10.1177/1073274817729076

Ejemplares similares

Effect of Metformin Use on Survival in Resectable Pancreatic Cancer: A Single-Institution Experience and Review of the Literature
por: Ambe, Chenwi M., et al.
Publicado: (2016)

External beam irradiation of myocardial carcinoid metastases: a case report
por: Strosberg, Jonathan, et al.
Publicado: (2007)

Case Report of Isolated Gastric Metastasis of Pancreatic Cancer From a Diagnostic Biopsy: Management of a Rare Oncologic Entity
por: Rothermel, Luke D., et al.
Publicado: (2020)

Expansion of tumor-infiltrating lymphocytes (TIL) from human pancreatic tumors
por: Hall, MacLean, et al.
Publicado: (2016)

Surgical and Pathologic Outcomes of Pancreatic Adenocarcinoma (PA) After Preoperative Ablative Stereotactic Magnetic Resonance Image Guided Adaptive Radiation Therapy (A-SMART)
por: Bryant, J.M., et al.
Publicado: (2022)

Neutrophil to lymphocyte ratio, not platelet to lymphocyte or lymphocyte to monocyte ratio, is predictive of patient survival after resection of early-stage pancreatic ductal adenocarcinoma
por: Pointer, David T., et al.
Publicado: (2020)

Multi-Institutional Outcomes of Patients Aged 75 years and Older With Pancreatic Ductal Adenocarcinoma Treated With 5-Fraction Ablative Stereotactic Magnetic Resonance Image-Guided Adaptive Radiation Therapy (A-SMART)
por: Bryant, JM, et al.
Publicado: (2023)

Evolving Diagnostic and Treatment Strategies for Pancreatic Neuroendocrine Tumors
por: Kulke, Matthew H, et al.
Publicado: (2011)

Real time ex vivo chemosensitivity assay for pancreatic adenocarcinoma
por: Kim, Dae Won, et al.
Publicado: (2023)

δ-Tocotrienol, a natural form of vitamin E, inhibits pancreatic cancer stem-like cells and prevents pancreatic cancer metastasis
por: Husain, Kazim, et al.
Publicado: (2017)

Hospital Surgical Volume Is Poorly Correlated With Delivery of Multimodal Treatment for Localized Pancreatic Cancer: A National Retrospective Cohort Study
por: Powers, Benjamin D., et al.
Publicado: (2022)

Case report: Irreversible electroporation for locally advanced pancreatic cancer
por: Orcutt, Sonia, et al.
Publicado: (2017)

The past, present, and future status of multimodality treatment for resectable/borderline resectable pancreatic ductal adenocarcinoma
por: Sakaguchi, Tatsuma, et al.
Publicado: (2020)

Minimally invasive appendectomy for resection of appendiceal mucocele: Case series and review of the literature
por: Orcutt, Sonia T., et al.
Publicado: (2017)

Comprehensive multimodal management of borderline resectable pancreatic cancer: Current status and progress
por: Wu, Hong-Yu, et al.
Publicado: (2023)

Diagnostic performance of endoscopic ultrasound-guided fine-needle aspiration for cystic and non-cystic pancreatic neuroendocrine tumors
por: Dhaliwal, Amaninder Jeet Singh, et al.
Publicado: (2019)

Treatment of Liver Metastases in Patients with Neuroendocrine Tumors
por: Granberg, Dan, et al.
Publicado: (2012)

Minimally invasive image-guided therapy of primary and metastatic pancreatic cancer
por: Bibok, Andras, et al.
Publicado: (2021)

Vitamin E δ-Tocotrienol Induces p27(Kip1)-Dependent Cell-Cycle Arrest in Pancreatic Cancer Cells via an E2F-1-Dependent Mechanism
por: Hodul, Pamela J., et al.
Publicado: (2013)

Prognostic Fifteen-Gene Signature for Early Stage Pancreatic Ductal Adenocarcinoma
por: Chen, Dung-Tsa, et al.
Publicado: (2015)

Borderline resectable pancreatic cancer: Certainties and controversies
por: Nappo, Gennaro, et al.
Publicado: (2021)

Neoadjuvant Treatment in Patients With Resectable and Borderline Resectable Pancreatic Cancer
por: Janssen, Quisette P., et al.
Publicado: (2020)

Editorial: Neoadjuvant treatment for resectable and borderline resectable pancreatic cancer
por: Massani, Marco, et al.
Publicado: (2023)

Neoadjuvant Treatment for Resectable and Borderline Resectable Pancreatic Cancer: Chemotherapy or Chemoradiotherapy?
por: Versteijne, Eva, et al.
Publicado: (2022)

Perioperative Predictors of Early Recurrence for Resectable and Borderline-Resectable Pancreatic Cancer
por: Imamura, Masafumi, et al.
Publicado: (2021)

Borderline resectable pancreatic cancer and vascular resections in the era of neoadjuvant therapy
por: Mikulic, Danko, et al.
Publicado: (2021)

A Phase I Safety, Pharmacokinetic, and Pharmacodynamic Presurgical Trial of Vitamin E δ-tocotrienol in Patients with Pancreatic Ductal Neoplasia
por: Springett, Gregory M., et al.
Publicado: (2015)

Giant symptomatic serous cystadenoma mimicking carcinoma: A case report and literature review
por: Pointer, Lauren, et al.
Publicado: (2019)

Contemporary management of borderline resectable pancreatic ductal adenocarcinoma
por: Lekka, Kyriaki, et al.
Publicado: (2019)

Contemporary Review of Borderline Resectable Pancreatic Ductal Adenocarcinoma
por: Bonds, Morgan, et al.
Publicado: (2019)

Cutting‐edge strategies for borderline resectable pancreatic cancer
por: Shinde, Rajesh S., et al.
Publicado: (2019)

Borderline Resectable Pancreatic Cancer: Challenges for Clinical Management
por: Fawaz, Ali, et al.
Publicado: (2022)

Prognostic value of pre-treatment F-18-FDG PET-CT in patients with hepatocellular carcinoma undergoing radioembolization
por: Abuodeh, Yazan, et al.
Publicado: (2016)

The impact of age and comorbidity on localized pancreatic cancer outcomes: A US retrospective cohort analysis with implications for surgical centralization
por: Powers, Benjamin D., et al.
Publicado: (2023)

FOLFIRINOX or Gemcitabine-based Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Cancer: A Multi-institutional, Patient-Level, Meta-analysis and Systematic Review
por: Eshmuminov, Dilmurodjon, et al.
Publicado: (2023)

A pilot study to evaluate tissue- and plasma-based DNA driver mutations in a cohort of patients with pancreatic intraductal papillary mucinous neoplasms
por: Park, Margaret A, et al.
Publicado: (2022)

TGFβ1 overexpression is associated with improved survival and low tumor cell proliferation in patients with early-stage pancreatic ductal adenocarcinoma
por: Glazer, Evan S., et al.
Publicado: (2016)

Optimizing neoadjuvant radiotherapy for resectable and borderline resectable pancreatic cancer using protons
por: Nichols, Romaine Charles, et al.
Publicado: (2019)

PANCREATIC NEUROENDOCRINE TUMORS: SURGICAL RESECTION
por: BELOTTO, Marcos, et al.
Publicado: (2019)

Irreversible electroporation in borderline resectable pancreatic adenocarcinoma for margin accentuation
por: Papoulas, Michail, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_6u13tejuhe1nfb2plsot6gvqqj